XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.20
+0.49%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.02
- Revenue estimate
- $101.6M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.18
- EPS estimate
- $0.01
- Revenue actual
- $91.0M
- Revenue estimate
- $90.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -279.0%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $14
- PT range
- $12 – $16
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $0.01 | -$0.18 | Miss -1582.70% | $91.0M |
| May 7, 2026 | -$0.00 | $0.01 | Beat 464.96% | $82.5M |
| Nov 6, 2025 | $0.01 | $0.00 | Miss -65.00% | $74.4M |
| Aug 7, 2025 | -$0.03 | -$0.01 | Beat 66.67% | $71.5M |
| May 8, 2025 | -$0.07 | -$0.06 | Beat 14.29% | $60.1M |
| Mar 6, 2025 | -$0.08 | -$0.03 | Beat 62.50% | $60.1M |
| Nov 8, 2024 | -$0.09 | -$0.06 | Beat 33.33% | $54.3M |
| Aug 8, 2024 | -$0.11 | -$0.10 | Beat 9.09% | $48.1M |
| May 9, 2024 | -$0.12 | -$0.14 | Miss -16.67% | $40.6M |
| Mar 6, 2024 | -$0.09 | -$0.10 | Miss -11.11% | $44.4M |
| Nov 9, 2023 | -$0.12 | -$0.09 | Beat 25.00% | $48.3M |
| Mar 8, 2023 | -$0.16 | -$0.10 | Beat 37.50% | $33.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026